ArticleHypertension research : official journal of the Japanese Society of Hypertension2025
Copy number loss Of APP cause thoracic aortic dissection.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thoracic aortic dissection (TAD) is a leading cause of sudden cardiovascular death. Although a limited number of copy number variations (CNVs) have been reported in small cohorts of patients with hereditary TAD or sporadic aortic dissection, a comprehensive investigation and functional validation of CNVs in sporadic TAD using large-scale whole genome sequencing (WGS) data remain lacking. To address this gap, we conducted whole genome sequencing in two independent case-control studies, involving 257 patients with sporadic TAD and 132 controls. We generated gene knockout mice to explore the role of the target gene in TAD progression in vivo. Additionally, RNA-seq analysis and molecular biology experiments were performed in vitro to elucidate the underlying mechanisms. In the discovery and validation cohorts, we identified four CNVs genes (DSCAM, APP, LINC00907, PROCR) potentially pivotal in the pathogenesis of TAD. Among these, only APP displayed reduced expression in the aortas of TAD patients compared to controls. Deletion of APP exacerbated elastic fiber fragmentation and promoted TAD formation in both β-aminopropionitrile (BAPN)-induced and PCSK9/AngII-induced TAD models. In vitro, the loss of APP facilitated vascular smooth muscle cells (VSMCs) apoptosis and the switch to a secretory phenotype. Our study is the first to report novel CNVs of APP in TAD, demonstrating that APP deficiency accelerates the initiation and progression of TAD. These findings suggest that APP represents a promising therapeutic target and a potential genetic risk factor for TAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.